Eupraxia Pharmaceuticals Inc.
News
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR Newswire Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of...\n more…
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CNW Group - News Releases Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference...\n more…
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 175.7% in August
Ticker Report Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 123,500 shares...\n more…
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
CNW Group - News Releases Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results Canada NewsWire VICTORIA, BC, Aug. 7, 2024 VICTORIA, BC...\n more…
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR Newswire Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility PR Newswire VICTORIA, BC, Aug. 2, 2024 The...\n more…
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
PR Newswire Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo PR...\n more…